Anti-CD38-targeted IGG4-attenuated IFNA TAK-573 Uses, Dosage, Side Effects and more
Anti-CD38-targeted IGG4-attenuated IFNA TAK-573 is under investigation in clinical trial NCT03215030 (A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM)).
| Attribute | Details |
|---|---|
| Trade Name | Anti-CD38-targeted IGG4-attenuated IFNA TAK-573 |
| Generic | Modakafusp alfa |
| Modakafusp alfa Other Names | Anti-CD38-targeted IGG4-attenuated IFNA TAK-573, Modakafusp alfa |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
